AR081252A1 - Compuestos para el tratamiento del sindrome metabolico - Google Patents
Compuestos para el tratamiento del sindrome metabolicoInfo
- Publication number
- AR081252A1 AR081252A1 ARP110101820A ARP110101820A AR081252A1 AR 081252 A1 AR081252 A1 AR 081252A1 AR P110101820 A ARP110101820 A AR P110101820A AR P110101820 A ARP110101820 A AR P110101820A AR 081252 A1 AR081252 A1 AR 081252A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- optionally substituted
- cycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Composición farmacéutica y usos como agonistas de GPR119. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde A es un fenilo para sustituido o un anillo heteroarilo de 6 miembros para sustituido que contienen uno a tres átomos de nitrógeno; R1 es hidrógeno, halo, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4 o alcoxialquilo C2-6; R2 es: un resto de fórmula (2), fenilo opcionalmente sustituido con uno o más grupos halo, metilo, halometilo o metoxi, o piridilo, N-piridonilo o N-pirazolilo, opcionalmente sustituido con uno o más grupos halo, alquilo C1-2 o halometilo; R3 es independientemente halo, metilo o halometilo; Z es -C(O)OR4, -C(O)R4, -S(O)2R4, -S(O)2N(alquil C1-3)R4, heteroarilo o -CH2-heteroarilo, y cuando p y q son ambos 0, Z también puede ser -CH2-fenilo, dicho fenilo está opcionalmente sustituido con uno o dos grupos independientemente seleccionados de alquilo C1-4, haloalquilo C1-4 y halo; R4 es arilo, heteroarilo, alquilo C2-6, cicloalquilo C3-6, heterociclilo C4-6, heterociclilalquilo C1-4, alcoxialquilo C2-6, arilalquilo C1-4, heteroarilalquilo C1-4 o cicloalquil C4-6alquilo C1-4, dicho cicloalquilalquilo C1-4 está opcionalmente sustituido con alquilo C1-4; en donde cuando Z es o incluye heteroarilo o cuando R4 es o incluye arilo o heteroarilo, dicho arilo o heteroarilo puede estar opcionalmente sustituido con uno o dos grupos seleccionados de halo, ciano, SF5, alquilo C1-4, haloalquilo C1-4, hidroxialquilo C1-5, alcoxi C1-4, alcoxialquilo C2-4, heterociclilo, heterociclilalquilo C1-4, heteroarilalquilo C1-4, alquilamino C1-4, alquilamino C1-4alquilo C1-4, cicloalquilo C3-6 y -(alquil C1-3)-(cicloalquilo C3-6), en donde los grupos cicloalquilo y alquilo están cada uno opcionalmente sustituidos con uno o dos grupos independientemente seleccionados de alquilo C1-4, hidroxi o halo; X se selecciona de CR5H, O, y NR6 en los cuales R5 y R6 son independientemente hidrógeno o alquilo C1-2; Y es Y1 o W-Y1, donde W es un anillo heteroarilo de 5 miembros que contiene uno o más heteroátomos seleccionados de N, O y S, e Y1 se seleccione de CR7H, O y NR8, en los cuales R7 es hidrógeno, alquilo C1-2, alcoxialquilo C2-6 o heterociclilo; en donde dicho alquilo C1-2 puede estar opcionalmente sustituido con ciano, hidroxi o halo y R8 es alquilo C1-4 o cicloalquilo C1-4, siempre que cuando Y es W-Y1, X es O y Y1 es CR7H, cuando Y1 es O ó NR8, X es CR5H y cuando X es O ó NR6, Y1 es CR7H; cada uno de R9 y R10 es independientemente H, halo, alquilo C1-2, haloalquilo C1-2, alcoxi C1-3 o hidroxi; o R9 y R10 se unen para formar un azabiciclo[3.3.1]nonano, un 3-oxa-7-azabiciclo[3.3.1]nonano o un azabiciclo[3.2.1]octano; R11 es H, halo, alquilo C1-2, haloalquilo C1-2 o alcoxi C1-3; m es 0, 1 ó 2; n es 0 ó 1; p y q son cada uno 0, 1 ó 2, siempre que 0 L p + q L 2; y r es 1 ó 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1008985.2A GB201008985D0 (en) | 2010-05-28 | 2010-05-28 | Novel compounds |
| GBGB1019547.7A GB201019547D0 (en) | 2010-11-19 | 2010-11-19 | Novel compounds |
| GB1103283.6A GB2488360A (en) | 2011-02-25 | 2011-02-25 | Heterocyclic GPCR agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081252A1 true AR081252A1 (es) | 2012-07-18 |
Family
ID=44227954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101820A AR081252A1 (es) | 2010-05-28 | 2011-05-27 | Compuestos para el tratamiento del sindrome metabolico |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR081252A1 (es) |
| TW (1) | TW201209054A (es) |
| WO (1) | WO2011147951A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| WO2013169531A1 (en) | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AU2016210544B2 (en) | 2015-01-23 | 2020-12-10 | Gvk Biosciences Private Limited | Inhibitors of TrkA kinase |
| WO2016131198A1 (en) * | 2015-02-18 | 2016-08-25 | Eli Lilly And Company | Pyrazole compounds |
| CN104788386A (zh) * | 2015-04-24 | 2015-07-22 | 湖南华腾制药有限公司 | 一种含氟嘧啶化合物的制备方法 |
| EP3749667A1 (en) | 2018-02-05 | 2020-12-16 | Alkermes, Inc. | Compounds for the treatment of pain |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
| CA2591738A1 (en) | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| EP1838311A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| CA2613236A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
| WO2007003961A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| BRPI0710839A2 (pt) | 2006-04-06 | 2011-08-23 | Prosidion Ltd | agonistas heterocìclicos de gpcr |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2008025799A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
| TWI387585B (zh) | 2006-09-01 | 2013-03-01 | Dow Agrosciences Llc | 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺 |
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| WO2008070692A2 (en) | 2006-12-06 | 2008-06-12 | Smithkline Beecham Corporation | Bicyclic compounds and use as antidiabetics |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| BRPI0806498A2 (pt) | 2007-01-04 | 2014-04-22 | Prosidion Ltd | Agonistas gpcr piperidina |
| PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CA2719507C (en) | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| GB0812031D0 (en) | 2008-07-01 | 2008-08-06 | 7Tm Pharma As | Thiazole derivatives |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| KR20110036609A (ko) | 2008-07-10 | 2011-04-07 | 프로시디온 리미티드 | 피페리디닐 ｇｐｃｒ 작용제 |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812642D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| US20110230507A1 (en) | 2008-07-10 | 2011-09-22 | Prosidion Limited | Piperidine GPCR Agonists |
| WO2010095663A1 (ja) | 2009-02-18 | 2010-08-26 | 武田薬品工業株式会社 | 縮合複素環化合物 |
-
2011
- 2011-05-24 TW TW100118140A patent/TW201209054A/zh unknown
- 2011-05-27 AR ARP110101820A patent/AR081252A1/es unknown
- 2011-05-27 WO PCT/EP2011/058703 patent/WO2011147951A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011147951A8 (en) | 2012-03-15 |
| WO2011147951A1 (en) | 2011-12-01 |
| TW201209054A (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| PE20190732A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR073687A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| PE20190653A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
| AR079231A1 (es) | Derivados de imidazoquinolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |